首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >The Therapeutic Effects of a Traditional Chinese Medicine Formula Wuzi Yanzong Pill for the Treatment of Oligoasthenozoospermia: A Meta-Analysis of Randomized Controlled Trials
【2h】

The Therapeutic Effects of a Traditional Chinese Medicine Formula Wuzi Yanzong Pill for the Treatment of Oligoasthenozoospermia: A Meta-Analysis of Randomized Controlled Trials

机译:中药复方五子衍宗丸治疗少精子症的疗效:随机对照试验的荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oligoasthenozoospermia is a crucial factor in male infertility. Wuzi Yanzong (WZYZ) pill is a popular traditional Chinese medicine (TCM) formula which has been used for male infertility treatment for years. However, its effects on semen quality remain controversial. We conducted a preregistered meta-analysis to assess the effect of WZYZ pill for the therapeutic effects on oligoasthenozoospermia. Five randomized controlled trials including 960 participants were selected from databases of domains in North-East Asian regions, PubMed, Embase, and Cochrane Library. WZYZ pill group yielded a greater mean increment on sperm concentration (5 trials: MD 5.99, 95% CI 2.12–9.85, P = 0.002), sperm motility (5 trials: MD 4.57, 95% CI 0.47–8.68, P = 0.03), sperm morphology (2 trials: MD −1.93, 95% CI −4.87–1.01, P = 0.20), activity of acrosomal enzyme (2 trials: MD 28.27, 95% CI 12.41–44.14, P < 0.01), volume of semen (2 trials: MD 0.56, 95% CI 0.21–0.91, P = 0.002), and a decrement of sperm DNA fragmentation index (2 trials: MD −3.82, 95% CI −6.45–−1.19, P = 0.004). However, qualities of selected studies were generally unsatisfactory, and there was inherent heterogeneity among some of the outcomes. Despite these limitations, the WZYZ pill improved sperm quality by improving several semen parameters and decreasing DNA damage in oligoasthenozoospermia patients.
机译:少精子症是男性不育的关键因素。五子衍宗(WZYZ)丸是一种流行的中药(TCM)配方,已被用于男性不育症治疗多年。但是,其对精液质量的影响仍存在争议。我们进行了预先注册的荟萃分析,以评估WZYZ丸对少精子症精子症的治疗效果。从东北亚地区,PubMed,Embase和Cochrane图书馆的域名数据库中选择了五个随机对照试验,包括960名参与者。 WZYZ丸组的精子浓度平均增加幅度更大(5个试验:MD 5.99,95%CI 2.12–9.85,P = 0.002),精子活力(5个试验:MD 4.57,95%CI 0.47–8.68,P = 0.03) ,精子形态(2个试验:MD −1.93、95%CI −4.87–1.01,P = 0.20),顶体酶活性(2个试验:MD 28.27、95%CI 12.41–44.14,P <0.01),精液量(2个试验:MD 0.56,95%CI 0.21-0.91,P = 0.002),并降低了精子DNA碎片指数(2个试验:MD -3.82,95%CI -6.45--1.19,P = 0.004)。但是,所选研究的质量通常不能令人满意,并且某些结果之间存在固有的异质性。尽管有这些局限性,WZYZ丸通过改善几个精液参数和减少少精症少精症患者的DNA损伤而改善了精子质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号